Entera Bio (ENTX) Free Cash Flow (2021 - 2026)

Entera Bio (ENTX) has reported Free Cash Flow for 6 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow fell 118.84% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.2 million (down 43.7% YoY) and the FY2025 annual result came in at -$7.5 million, down 9.62% from the prior year.
• Free Cash Flow slipped to -$3.1 million in Q1 2026 per ENTX's latest filing, from -$1.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for ENTX reached as high as -$1.3 million in Q2 2024 and fell as low as -$4.8 million in Q1 2022.
• A 5-year average of -$2.2 million and a median of -$1.9 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 66.36% — and 2026, when it slumped 118.84%.
• Year by year, Free Cash Flow stood at -$2.0 million in 2022, then plunged by 30.19% to -$2.6 million in 2023, then jumped by 43.94% to -$1.5 million in 2024, then dropped by 26.53% to -$1.9 million in 2025, then slumped by 66.13% to -$3.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$3.1 million, -$1.9 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.